Myeloproliferative Disorder (MPD) and Myelodisplastic Syndrome (MPS)
H8701; CD34-selection for ex vivo T-cell depletion of mobilized peripheral blood stem cells for recipients of HLA haploidentical related donor stem cell grafts receiving intensive conditioning (MOHEL): This study uses a monoclonal antibody and high dose chemotherapy and radiotherapy combined with a haploidentical allogeneic stem cell transplantation to treat pediatric patients with hematologic malignancies.
H8713; Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancy, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning with Campath 1H (HIMSUM): This study uses a monoclonal antibody, low dose chemotherapy and radiation combined with haploidentical allogeneic stem cell transplantation to treat patients with hematologic malignancies who have already received a stem cell transplant or who also have other complications such as kidney, liver, or heart disease.
H29458; Randomized, multi-center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN 0901): This study compares two different types of conditioning for stem cell transplants in patients with Myelodysplastic syndrome or Acute Myeloid Leukemia. The two types of conditioning are reduced intensity conditioning and standard intensity conditioning.
H26558; Umbilical Cord Blood Transplant for Children with Myeloid Hematological Malignancies (UCAML): This study uses Umbilical Cord Stem Cells following high dose chemotherapy to treat patients with myeloid hematological malignancies.
H28256; Inducible Caspase-9 Suicide Gene (DOTTI): This study uses haploidentical stem cells following conditioning. The stem cells have been transduced with a suicide gene that allows them to be destroyed if they cause Graft vs. Host Disease)